CENTOGENE Receives Delisting Notice From Nasdaq
CENTOGENE received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE’S common stock from Nasdaq.
CENTOGENE received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE’S common stock from Nasdaq.
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
CENTOGENE today announced the voting results of the Company’s 2024 Annual General Meeting. Shareholders voted in favor of all proposals.
Reported Full Year 2023 total revenues
Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical research; Companies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royalties
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
CENTOGENE Receives Nasdaq Non-Compliance Notice April 2024
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of the Rare Disease, Human Pre-TCRα Deficiency
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development
Partners able to claim up to 30% tax relief
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
